GlobeNewsWire · CELC · October 24, 2026

Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026

Get the app for more

Explore stock news, insights and company research.